PMID- 30983803
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 0974-2727 (Print)
IS  - 0974-7826 (Electronic)
IS  - 0974-2727 (Linking)
VI  - 11
IP  - 1
DP  - 2019 Jan-Mar
TI  - Correlation of vascular endothelial growth factor and vascular endothelial growth 
      factor receptor-1 levels in serum and thyroid nodules with histopathological and 
      radiological variables.
PG  - 51-57
LID - 10.4103/JLP.JLP_41_18 [doi]
AB  - BACKGROUND/AIM: Vascular endothelial growth factor (VEGF) is a major cytokine in 
      angiogenesis and has a role on aggressivity of various tumors. The expression of 
      VEGF has been shown to increase in differential thyroid cancer. The aim of the 
      study was to evaluate serum and intranodular VEGF (nVEGF) and VEGF receptor-1 
      (VEGFR-1) levels in patients with thyroid nodules and their relevance to 
      ultrasonographic and pathological results. MATERIALS AND METHODS: A total of 
      eighty patients were included in the study. Thyroid fine-needle aspiration 
      biopsies were performed, and the levels of serum and nVEGF and VEGFR-1 were 
      measured. Any possible correlations between serum and nVEGF, VEGFR-1, and 
      biochemical/radiological variables were investigated. RESULTS: There were no 
      significant differences between serum VEGF (sVEGF), nVEGF, sVEGFR-1, nVEGFR-1 
      levels, number of nodules, size of nodules, and benign and malignant 
      ultrasonographic features. sVEGF and nVEGF were higher in malignant or suspicious 
      nodules than that in benign nodules, but did not reach statistical significance 
      (P > 0.05). sVEGFR-1 and nVEGFR-1 levels were higher in hyperthyroid patients 
      than that in euthyroid patients (P < 0.05 and P = 0.003, respectively). nVEGFR-1 
      level was higher in hypothyroid patients than that in euthyroid patients (P = 
      0.016). sVEGF level was found to be higher in hyperactive nodules than that in 
      others. Both sVEGFR-1 (P = 0.008) and nVEGF levels (P = 0.01) significantly 
      increased with increasing age. nVEGFR-1 decreased with increasing body mass index 
      (BMI) (P = 0.004). CONCLUSIONS: Our study showed the relationships of sVEGF, 
      nVEGF, sVEGFR-1, and nVEGFR-1 levels with age, gender, BMI, and hyperthyroidism. 
      To determine the role of VEGF/VEGFR-1 in thyroid nodules, further studies are 
      required with a large number of patients.
FAU - Haytaoglu, Gurkan
AU  - Haytaoglu G
AD  - Department of Internal Medicine, Faculty of Medicine, Bulent Ecevit University, 
      Zonguldak, Turkey.
FAU - Kuzu, Fatih
AU  - Kuzu F
AD  - Department of Internal Medicine, Division of Endocrinology and Metabolism, Evliya 
      Celebi Training and Research Hospital, Dumlupinar University, Kutahya, Turkey.
FAU - Arpaci, Dilek
AU  - Arpaci D
AD  - Department of Internal Medicine, Division of Endocrinology and Metabolism, 
      Faculty of Medicine, Bulent Ecevit University, Zonguldak, Turkey.
FAU - Altas, Ayfer
AU  - Altas A
AD  - Department of Internal Medicine, Faculty of Medicine, Bulent Ecevit University, 
      Zonguldak, Turkey.
FAU - Can, Murat
AU  - Can M
AD  - Department of Biochemistry, Faculty of Medicine, Bulent Ecevit University, 
      Zonguldak, Turkey.
FAU - Barut, Figen
AU  - Barut F
AD  - Department of Pathology, Faculty of Medicine, Bulent Ecevit University, 
      Zonguldak, Turkey.
FAU - Kokturk, Furuzan
AU  - Kokturk F
AD  - Department of Biostatistics, Faculty of Medicine, Bulent Ecevit University, 
      Zonguldak, Turkey.
FAU - Ilikhan, Sevil Uygun
AU  - Ilikhan SU
AD  - Department of Internal Medicine, Faculty of Medicine, Bulent Ecevit University, 
      Zonguldak, Turkey.
FAU - Bayraktaroglu, Taner
AU  - Bayraktaroglu T
AD  - Department of Internal Medicine, Division of Endocrinology and Metabolism, 
      Faculty of Medicine, Bulent Ecevit University, Zonguldak, Turkey.
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - J Lab Physicians
JT  - Journal of laboratory physicians
JID - 101551511
PMC - PMC6437829
OTO - NOTNLM
OT  - Malignancy
OT  - nodule
OT  - thyroid
COIS- There are no conflicts of interest.
EDAT- 2019/04/16 06:00
MHDA- 2019/04/16 06:01
PMCR- 2019/01/01
CRDT- 2019/04/16 06:00
PHST- 2019/04/16 06:00 [entrez]
PHST- 2019/04/16 06:00 [pubmed]
PHST- 2019/04/16 06:01 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - JLP-11-51 [pii]
AID - 10.4103/JLP.JLP_41_18 [doi]
PST - ppublish
SO  - J Lab Physicians. 2019 Jan-Mar;11(1):51-57. doi: 10.4103/JLP.JLP_41_18.